A carregar...
ALK inhibitors, resistance development, clinical trials
The treatment of advanced non-small-cell lung cancer (nsclc) has undergone a paradigm shift since the early 2000s. The identification of molecular subtypes of the disease, based on oncogenic drivers, has led to the development of personalized medicine and the ability to deliver molecularly targeted...
Na minha lista:
| Publicado no: | Curr Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Multimed Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6001759/ https://ncbi.nlm.nih.gov/pubmed/29910648 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3760 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|